The FDA has now required manufacturers to add a black box warning of the risk of tardive dyskinesia (TD) with chronic or high dose metoclopromide use. Symptoms of TD are more likely to develop in older women, and risk correlates with the number of doses and length of treatment. The FDA concludes that chronic metoclopromide use “…should be avoided in all but rare cases…” (FDA link)
Share This Post
Categories
Related Posts
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
Leave A Comment